Neuberger Berman Group LLC decreased its position in shares of Haemonetics Corp. (NYSE:HAE) by 2.2% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,881,814 shares of the company’s stock after selling 42,095 shares during the period. Neuberger Berman Group LLC owned approximately 3.67% of Haemonetics Corp. worth $68,140,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Cardinal Capital Management raised its position in Haemonetics Corp. by 11.3% in the third quarter. Cardinal Capital Management now owns 9,916 shares of the company’s stock worth $359,000 after buying an additional 1,010 shares during the last quarter. Aperio Group LLC purchased a new position in Haemonetics Corp. during the third quarter worth about $264,000. Great West Life Assurance Co. Can raised its position in Haemonetics Corp. by 4.5% in the third quarter. Great West Life Assurance Co. Can now owns 69,798 shares of the company’s stock worth $2,526,000 after buying an additional 3,011 shares during the last quarter. Hermes Investment Management Ltd. raised its position in Haemonetics Corp. by 7.2% in the third quarter. Hermes Investment Management Ltd. now owns 671,536 shares of the company’s stock worth $24,316,000 after buying an additional 44,912 shares during the last quarter. Finally, American Capital Management Inc. purchased a new position in Haemonetics Corp. during the third quarter worth about $20,732,000. 99.51% of the stock is owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for Haemonetics Corp. (NYSE:HAE)

Shares of Haemonetics Corp. (NYSE:HAE) opened at 39.61 on Wednesday. The stock’s 50 day moving average is $36.25 and its 200-day moving average is $33.49. The firm’s market cap is $2.05 billion. Haemonetics Corp. has a 12-month low of $25.98 and a 12-month high of $39.96.

Haemonetics Corp. (NYSE:HAE) last posted its quarterly earnings data on Monday, November 7th. The company reported $0.46 earnings per share for the quarter, beating the consensus estimate of $0.35 by $0.11. The firm earned $220.30 million during the quarter, compared to analysts’ expectations of $210.72 million. Haemonetics Corp. had a negative net margin of 6.48% and a positive return on equity of 10.99%. The company’s quarterly revenue was up .3% compared to the same quarter last year. During the same quarter last year, the company posted $0.44 EPS. On average, analysts anticipate that Haemonetics Corp. will post $1.50 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Neuberger Berman Group LLC Sells 42,095 Shares of Haemonetics Corp. (HAE)” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another domain, it was stolen and reposted in violation of US and international trademark & copyright laws. The correct version of this report can be accessed at https://www.thecerbatgem.com/2016/11/30/neuberger-berman-group-llc-sells-42095-shares-of-haemonetics-corp-hae.html.

A number of brokerages have recently weighed in on HAE. CJS Securities lowered shares of Haemonetics Corp. from a “market outperform” rating to a “market perform” rating and set a $35.00 price target for the company. in a research note on Tuesday, September 20th. BTIG Research reaffirmed a “neutral” rating on shares of Haemonetics Corp. in a research note on Monday, November 7th. Jefferies Group upped their price target on shares of Haemonetics Corp. from $32.00 to $40.00 and gave the stock a “buy” rating in a research note on Tuesday, August 2nd. Benchmark Co. upped their price target on shares of Haemonetics Corp. from $32.00 to $34.00 and gave the stock a “hold” rating in a research note on Monday, November 7th. Finally, Barrington Research lowered shares of Haemonetics Corp. from an “outperform” rating to a “market perform” rating in a research note on Wednesday, August 3rd. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and two have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $34.57.

About Haemonetics Corp.

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.

5 Day Chart for NYSE:HAE

Receive News & Stock Ratings for Haemonetics Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Corp. and related stocks with our FREE daily email newsletter.